Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

BioLineRx (BLRX) Consolidated Net Income: 2023-2025

Historic Consolidated Net Income for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to -$2.0 million.

  • BioLineRx's Consolidated Net Income rose 45.04% to -$2.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$7.7 million, marking a year-over-year increase of 80.04%. This contributed to the annual value of -$11.3 million for FY2024, which is 76.25% up from last year.
  • As of Q2 2025, BioLineRx's Consolidated Net Income stood at -$2.0 million, which was down 2.84% from -$2.0 million recorded in Q1 2025.
  • Over the past 5 years, BioLineRx's Consolidated Net Income peaked at $54,000 during Q4 2024, and registered a low of -$19.5 million during Q4 2023.
  • In the last 3 years, BioLineRx's Consolidated Net Income had a median value of -$3.8 million in 2024 and averaged -$6.3 million.
  • Data for BioLineRx's Consolidated Net Income shows a peak YoY surged of 100.28% (in 2024) over the last 5 years.
  • BioLineRx's Consolidated Net Income (Quarterly) stood at -$19.5 million in 2023, then surged by 100.28% to $54,000 in 2024, then spiked by 45.04% to -$2.0 million in 2025.
  • Its Consolidated Net Income was -$2.0 million in Q2 2025, compared to -$2.0 million in Q1 2025 and $54,000 in Q4 2024.